Clinical trial NCT05358327: Treatment for Lifting Upper Arm Lax Skin
Official title: Safety and Efficacy of Sofwave Treatment to Lift Upper Arm Lax Skin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lax Skin
Keywords: upper arms, lax skin
Lead sponsor: Sofwave Medical LTD
Sponsor class: INDUSTRY
First posted: 2022-05-03
Enrollment: 50
Sex: ALL
Minimum age (years): 35
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.

Detailed description: Eligible patients will receive 2 treatments on both upper arms (4-6 weeks apart) using the Sofwave System.

Treatment may be administered after the enrollment and screening at the first visit, or it may occur later following the enrollment and screening activities based on site scheduling availabilities. All patients will return to the clinic for follow up visit at 3 months ± 2 weeks post last treatment (FU1).

Methodology described in the protocol to evaluate efficacy and safety of treatments will be carried out at each visit at the clinic.

Eligibility criteria: Inclusion Criteria:

1. Male or female subjects \> 35 years of age and \< 70 years of age.
2. Not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence.
3. Desire to undergo upper arms skin lax lifting treatments.
4. Subject has clearly visible lax skin on the upper arm, which in the investigator's opinion, may benefit from the treatment.
5. Subject agrees to maintain his/her weight (i.e., within 5% of total body weight) by not making any major changes in their diet or exercise routine during the course of the study.
6. Able and willing to comply with all visits, treatments and evaluations schedules and requirements.
7. Willing to have research photos taken of treatment areas.
8. Subject agrees not to undergo any other upper arm skin lax treatments for a period of 3 months following Sofwave treatment.
9. Able to understand and provide written Informed Consent.

Exclusion Criteria:

1. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
2. Skin disorders (skin infections or rashes, extensive scarring, psoriasis, etc.) in the treatment area.
3. Medical disorder that would hinder the wound healing or immune response (such as blood disorder, inflammatory disease, etc.).
4. History of Epileptic seizures.
5. Known allergy to lidocaine or epinephrine or antibiotics.
6. Active malignancy or history of malignancy in the past 5 years.
7. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process).
8. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
9. Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen.
10. History of significant lymphatic drainage problems.
11. Currently heavy smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years.
12. History of chronic drug or alcohol abuse.
13. History of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.
14. Currently taking or has taken diet pills or weight control supplements within the past month.
15. BMI\>=30kg/m2
16. Non-stable weight nominally ±5% for at the past month.
17. Active implanted device such as a pacemaker, defibrillator, or drug delivery system.
18. History of epidermal or dermal disorders (particularly involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders.
19. History of a fat reduction procedure (e.g., liposuction, surgery, lipolytic agents, etc.).
20. History of prior surgery in the upper arms.
21. Excessive subcutaneous fat on the upper arms.
22. Severe solar elastosis on the intended to treat area.
23. Significant scarring, atrophic scars in the area to be treated, or has a history of atrophic scars or keloids or prone to bruising.
24. Tattoo or former tattoo at or near treatment area.
25. Presence of an implant in or adjacent to area of intended treatment (upper arms).
26. History of ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep peeling within the past 12 months on the intended to treat area.
27. Inability to understand the protocol or to give informed consent.
28. On-going use of psychiatric medication.
29. Unable or unwilling to comply with the study requirements and procedures.
30. Currently enrolled in a clinical study of any other unapproved investigational drug or device.
31. Any other condition that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Primary outcomes:
measure: Rate of improvement of upper arms lax skin
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: Laser & Skin Surgery Center of Northern California
state: California
city: Lincolnshire
country: United States
facility: Advanced Dermatology
state: Illinois
city: New York
country: United States
facility: Laser & Skin Surgery Center of New York®
state: New York
city: Ardmore
country: United States
facility: Main Line Center for Laser Surgery
state: Pennsylvania
Study officials:
affiliation: CMO
name: Ruthie Amir, MD
role: STUDY_DIRECTOR
References: